Dazodalibep is a Fusion Protein owned by Horizon Therapeutics, and is involved in 10 clinical trials, of which 4 were completed, 3 are ongoing, and 3 are planned.

Dazodalibep (VIB-4920, MEDI-4920) is a CD40 ligand inhibitor. CD40 is expressed as a receptor on B-cells that deliver contact-dependent T helper signals to B-cells through interaction with CD40 ligand (CD40L, CD154). The pivotal role played by CD40-CD40L interaction is in B-lineage cell development. CD40 signaling also provides critical functions in stimulating antigen presentation, priming of helper and cytotoxic T-cells and a variety of inflammatory reactions. Dysregulations in the CD40-CD40L co-stimulation pathway leads to inflammatory conditions.

The revenue for Dazodalibep is expected to reach a total of $2.1bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Dazodalibep NPV Report.

Dazodalibep was originated by MedImmune and is currently owned by Horizon Therapeutics.

Dazodalibep Overview

Dazodalibep (VIB-4920, MEDI-4920) is under development for the treatment of focal segmental glomerulosclerosis, kidney transplant rejection, rheumatoid arthritis and Sjogren's syndrome. It is administered by intravenous route. The drug candidate is a biological agent derived from third fibronectin type III domain of human tenascin C antagonizing the CD40 ligand. It is an anti-CD40L-Tn3 fusion protein.

Horizon Therapeutics Overview

Horizon Therapeutics formerly Horizon Pharma, is a pharmaceutical company, which develops and commercializes medical products for the treatment of rare, autoimmune, arthritis and severe inflammatory diseases. It markets medicines through its orphan, primary care and rheumatology business units. A few of the company’s marketed products include Actimmune, Buphenyl, Duexis, Krystexxa, Pennsaid, Procysbi, Quinsair, Ravicti, Rayos, Tepezza, Uplinza, and Vimovo. Horizon Therapeutics provides products and services to patients and healthcare professionals in the US. The company operates through offices in the US, Switzerland, Luxembourg, Bermuda, Germany, Canada, and Israel. Horizon Therapeutics is headquartered in Dublin, Ireland.

The company reported revenues of (US Dollars) US$3,226.4 million for the fiscal year ended December 2021 (FY2021), an increase of 46.6% over FY2020. In FY2021, the company’s operating margin was 16.8%, compared to an operating margin of 20.8% in FY2020. In FY2021, the company recorded a net margin of 16.6%, compared to a net margin of 17.7% in FY2020. The company reported revenues of US$925.4 million for the third quarter ended September 2022, an increase of 5.6% over the previous quarter.

Quick View – Dazodalibep

Report Segments
  • Innovator
Drug Name
  • Dazodalibep
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Genito Urinary System And Sex Hormones
  • Immunology
Key Companies
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.